The closing price of Iovance Biotherapeutics Inc. (NASDAQ: IOVA) was $6.28 for the day, down -3.24% from the previous closing price of $6.49. In other words, the price has decreased by -$0.21 from its previous closing price. On the day, 4007683 shares were traded. IOVA stock price reached its highest trading level at $6.61 during the session, while it also had its lowest trading level at $6.11.
Our analysis of IOVA’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 4.70 and its Current Ratio is at 4.70. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
Stifel Upgraded its Hold to Buy on January 28, 2022, whereas the target price for the stock was revised from $23 to $25.
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Jun 01 when Vogt Frederick G bought 1,000 shares for $6.44 per share. The transaction valued at 6,440 led to the insider holds 1,000 shares of the business.
Rothbaum Wayne P. bought 500,000 shares of IOVA for $3,215,500 on Jun 01. The Director now owns 8,067,333 shares after completing the transaction at $6.43 per share. On May 31, another insider, Rothbaum Wayne P., who serves as the Director of the company, bought 500,000 shares for $6.77 each. As a result, the insider paid 3,384,550 and bolstered with 7,567,333 shares of the company.
Stock Price History:
Over the past 52 weeks, IOVA has reached a high of $20.60, while it has fallen to a 52-week low of $5.42. The 50-Day Moving Average of the stock is 9.14, while the 200-Day Moving Average is calculated to be 12.22.
IOVA traded an average of 2.51M shares per day over the past three months and 4.68M shares per day over the past ten days. A total of 157.82M shares are outstanding, with a floating share count of 146.85M. Shares short for IOVA as of Oct 13, 2022 were 18.17M with a Short Ratio of 17.26M, compared to 19.54M on Sep 14, 2022. Therefore, it implies a Short% of Shares Outstanding of 11.51% and a Short% of Float of 12.10%.
The firm’s stock currently is rated by 14 analysts. On average, analysts expect EPS of -$0.64 for the current quarter, with a high estimate of -$0.56 and a low estimate of -$0.7, while EPS last year was -$0.55. The consensus estimate for the next quarter is -$0.66, with high estimates of -$0.52 and low estimates of -$0.9.
Analysts are recommending an EPS of between -$2.29 and -$2.8 for the fiscal current year, implying an average EPS of -$2.51. EPS for the following year is -$2.41, with 13 analysts recommending between -$1.9 and -$3.15.